Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.


A phase III, multi-centre randomised trial of adding nitroglycerin to first line chemotherapy for advanced non-small cell lung cancer.

The trial opened in May 2009 with recruitment closing in April 2014, with 372 patients randomised from 29 active sites. Follow-up has been completed and all sites are to be closed by December. The study results were presented at ESMO 2014 and ALLC 2014 and the final results have been submitted for publication.


Study Chair: Andrew Davidson

Email: andrew.davidson@health.wa.gov.au

CTC Trial Coordinator: Nick Muljadi

Email: nitro@ctc.usyd.edu.au